RGC vs. SMMT: A Head-to-Head Stock Comparison

Updated on October 16, 2025

Here’s a clear look at RGC and SMMT, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	RGC	SMMT
Company Name	Regencell Bioscience Holdings Limited	Summit Therapeutics Inc.
Country	Hong Kong	United States
GICS Sector	Health Care	Health Care
GICS Industry	Pharmaceuticals	Biotechnology
Market Capitalization	9.59 billion USD	17.34 billion USD
Exchange	NasdaqCM	NasdaqGM
Listing Date	July 16, 2021	March 5, 2015
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of RGC and SMMT by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

RGC vs. SMMT: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	RGC	SMMT
5-Day Price Return	26.66%	11.84%
13-Week Price Return	3.83%	-5.66%
26-Week Price Return	3,133.87%	23.43%
52-Week Price Return	18,127.27%	23.36%
Month-to-Date Return	29.77%	12.97%
Year-to-Date Return	15,323.08%	30.79%
10-Day Avg. Volume	0.24M	2.86M
3-Month Avg. Volume	1.00M	4.08M
3-Month Volatility	90.19%	83.23%
Beta	2.26	-1.64

Profitability

Return on Equity (TTM)

RGC

-54.75%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.85%
Q1: 5.40%
Min: -10.91%

RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

SMMT

-52.22%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

SMMT has a negative Return on Equity of -52.22%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

RGC vs. SMMT: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Net Profit Margin (TTM)

RGC

Pharmaceuticals Industry

Max: 40.67%
Q3: 19.07%
Median: 12.31%
Q1: 4.50%
Min: -9.91%

Net Profit Margin data for RGC is currently unavailable.

SMMT

-9,027.08%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

SMMT has a negative Net Profit Margin of -9,027.08%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

RGC vs. SMMT: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Operating Profit Margin (TTM)

RGC

Pharmaceuticals Industry

Max: 45.78%
Q3: 23.14%
Median: 16.68%
Q1: 7.98%
Min: -7.13%

Operating Profit Margin data for RGC is currently unavailable.

SMMT

-8,108.33%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

SMMT has a negative Operating Profit Margin of -8,108.33%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

RGC vs. SMMT: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Profitability at a Glance

Symbol	RGC	SMMT
Return on Equity (TTM)	-54.75%	-52.22%
Return on Assets (TTM)	-51.38%	-41.67%
Net Profit Margin (TTM)	--	-9,027.08%
Operating Profit Margin (TTM)	--	-8,108.33%
Gross Profit Margin (TTM)	--	--

Financial Strength

Current Ratio (MRQ)

RGC

42.68

Pharmaceuticals Industry

Max: 4.65
Q3: 2.64
Median: 1.85
Q1: 1.26
Min: 0.78

RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

SMMT

5.13

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

SMMT’s Current Ratio of 5.13 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

RGC vs. SMMT: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Debt-to-Equity Ratio (MRQ)

RGC

0.00

Pharmaceuticals Industry

Max: 1.75
Q3: 0.82
Median: 0.35
Q1: 0.13
Min: 0.00

Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

SMMT

0.00

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

SMMT’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

RGC vs. SMMT: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Interest Coverage Ratio (TTM)

RGC

Pharmaceuticals Industry

Max: 103.95
Q3: 43.60
Median: 9.83
Q1: 2.37
Min: -42.71

Interest Coverage Ratio data for RGC is currently unavailable.

SMMT

-121.35

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

SMMT has a negative Interest Coverage Ratio of -121.35. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

RGC vs. SMMT: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Financial Strength at a Glance

Symbol	RGC	SMMT
Current Ratio (MRQ)	42.68	5.13
Quick Ratio (MRQ)	41.89	4.94
Debt-to-Equity Ratio (MRQ)	0.00	0.00
Interest Coverage Ratio (TTM)	--	-121.35

Growth

Revenue Growth

RGC vs. SMMT: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

RGC vs. SMMT: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

RGC

0.00%

Pharmaceuticals Industry

Max: 7.14%
Q3: 3.45%
Median: 2.17%
Q1: 0.33%
Min: 0.00%

RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

SMMT

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

SMMT currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

RGC vs. SMMT: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Dividend Payout Ratio (TTM)

RGC

0.00%

Pharmaceuticals Industry

Max: 199.58%
Q3: 97.17%
Median: 53.47%
Q1: 22.97%
Min: 0.00%

RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

SMMT

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

SMMT has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

RGC vs. SMMT: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Dividend at a Glance

Symbol	RGC	SMMT
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

RGC

Pharmaceuticals Industry

Max: 45.19
Q3: 27.91
Median: 20.59
Q1: 15.08
Min: 3.79

P/E Ratio data for RGC is currently unavailable.

SMMT

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

P/E Ratio data for SMMT is currently unavailable.

RGC vs. SMMT: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Price-to-Sales Ratio (TTM)

RGC

Pharmaceuticals Industry

Max: 8.87
Q3: 4.56
Median: 2.14
Q1: 1.58
Min: 0.11

P/S Ratio data for RGC is currently unavailable.

SMMT

18,106.89

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

With a P/S Ratio of 18,106.89, SMMT trades at a valuation that eclipses even the highest in the Biotechnology industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

RGC vs. SMMT: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Price-to-Book Ratio (MRQ)

RGC

9.57

Pharmaceuticals Industry

Max: 9.78
Q3: 4.99
Median: 2.48
Q1: 1.53
Min: 0.59

RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

SMMT

60.92

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

At 60.92, SMMT’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

RGC vs. SMMT: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Valuation at a Glance

Symbol	RGC	SMMT
Price-to-Earnings Ratio (TTM)	--	--
Price-to-Sales Ratio (TTM)	--	18,106.89
Price-to-Book Ratio (MRQ)	9.57	60.92
Price-to-Free Cash Flow Ratio (TTM)	--	--